Maynard Um
-
-
-
-
-
-
-
Rigel Pharmaceuticals regains rights as Lilly terminates license deal
-
-
-
-
-
-
-
Rigel Pharmaceuticals (RIGL) PT Raised to $69 at Citi
-
-
-
-
-
-
-
Rigel Pharma (RIGL) Announces Settlement Agreement Resolving TAVALISSE Patent Litigation
-
-
-
-
-
-
-
Rigel Pharma's (RIGL) Fostamatinib Studied by National Institute of Health in Patients with Sickle Cell Disease
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Rigel Pharmaceuticals (RIGL)
-
-
-
-
-
-
-
Rigel Pharma (RIGL) Completes Transfer of GAVRETO NDA
439,170 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

